Quell, a U.K. based biotech company, has recently secured its first partnership with AstraZeneca (AZ) on June 9th. The partnership will focus on developing a new class of drugs that target regulatory T cells (Tregs) to treat autoimmune and inflammatory diseases.
Tregs are a type of immune cell that play a crucial role in maintaining immune homeostasis and preventing autoimmune diseases. However, in some cases, Tregs can become dysfunctional or depleted, leading to the development of autoimmune and inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.
Quell’s approach to targeting Tregs involves developing small molecule drugs that selectively activate or inhibit specific Treg pathways. This approach has the potential to provide more precise and effective treatments for autoimmune and inflammatory diseases compared to current therapies that broadly suppress the immune system.
The partnership with AZ will provide Quell with access to AZ’s drug discovery and development expertise, as well as its extensive network of resources and capabilities. In return, AZ will have the option to license Quell’s Treg-targeting drugs for further development and commercialization.
This partnership is a significant milestone for Quell, as it validates the potential of its Treg-targeting approach and provides the company with the resources needed to advance its drug development programs. It also highlights the growing interest in Treg-targeting therapies among pharmaceutical companies, as they offer a promising new approach to treating autoimmune and inflammatory diseases.
Overall, the partnership between Quell and AZ represents an exciting development in the field of Treg-targeting therapies and holds great promise for the future of autoimmune and inflammatory disease treatment.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- EVM Finance. Unified Interface for Decentralized Finance. Access Here.
- Quantum Media Group. IR/PR Amplified. Access Here.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Source: Plato Data Intelligence.